Erythema Multiforme - 15 Studies Found Completed : Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05% : Plaque Psoriasis : 2013-06-26 : Drug: Clobex Spray Other Name: Clobetasol propionate spray Recruiting : A Randomized Two Arm Phase II Trial of Pembrolizumab Alone or Sequentially Following Single Fraction Non-ablative Radiation to One of the Target Lesions, in Previously Treated Patients With Stage IV NSCLC : Stage IV Non-Small Cell Lung Cancer : 2016-01-14 : Drug: Pembrolizumab 200mg Pemb Not yet recruiting : Discerning Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Guided Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy : Prostate Cancer Magnetic Resonance Imaging Device: MRI/ultrasound transperineal fusion-guided prostate biopsy Completed : Liposomal Lurtotecan in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer : Head and Neck Cancer : 2001-08-10 : Drug: liposomal lurtotecan Active, not recruiting : Drug-eluting Balloon vs. Conventional Balloon in the Treatment of (re)Stenosis (Dialysis Fistulae) : Vascular Access Complication Restenosis, Vascular Graft Di : 2017-01-19 : Device: Conventional angioplasty Recruiting : HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction : Stevens-Johnson Syndrome Kidney Failure, Chronic : 2017-02-06 : Genetic: HLA-B*5801 test Check whether a participant has HLA-B*5801 allele or not, before administration Not yet recruiting : Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis : Stevens-Johnson Syndrome Toxic Epidermal Necrolyses : 2016-11-25 : Drug: cyclosporin A Other Name Completed : Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. : Stevens-Johnson Syndrome Toxic Epidermal Necrolysis : 2012-09-20 : Drug: Intravenous immunoglobulin Completed : Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye : Stevens-Johnson Syndrome : 2010-11-08 : Drug: 0.05%cyclosporin eye drop use twice daily for 6 months Withdrawn : Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) : Stevens-Johnson Syndrome Corneal Blindness : 2010-11-19 : Drug: Infliximab The drug will be administered intravenously every month for 110 weeks (duration of the Next >>>
